Overview, Management of the Infections in Psoriatic Patients Treated with Systemic Therapies: A lesson from the immunopathogenesis of psoriasis
Keywords:
psoriasis, infection, prevention, management, covid-19Abstract
Modern treatments continue to be developed, based on identifying targets within the innate and adaptive immune pathways associated with psoriasis. Whilst there is a sound biologic rationale for increased risk of infection following treatment with immunomodulators, the clinical evidence is confounded by these agents being used in patients affected with several comorbidities. In an era characterized by ever greater and growing risk of infections, it is necessary to always be updated on this risk. In this review, we will discuss recent updates in psoriasis immunopathogenesis as a rationale for systemic therapy, outline the risk of infections linked to the disease itself and systemic therapy as well, and provide an overview about the management of infections.
References
Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754-766. doi:10.1016/S0140-6736(21)00184-7
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. doi:10.1016/S0140-6736(14)61909-7
Nickoloff BJ, Qin JZ, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33(1-2):45-56. doi:10.1007/s12016-007-0039-2
Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302-309. doi:10.1038/cmi.2012.15
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66-73. doi:10.1016/j.jaut.2015.07.008
Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009;10(3):201-209. doi:10.1038/gene.2009.11
Capon F. The Genetic Basis of Psoriasis. Int J Mol Sci. 2017;18(12):2526. Published 2017 Nov 25. doi:10.3390/ijms18122526
Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies. Genes Immun. 2019;20(5):415-425. doi:10.1038/s41435-019-0067-y
Ray-Jones H, Eyre S, Barton A, Warren RB. One SNP at a Time: Moving beyond GWAS in Psoriasis. J Invest Dermatol. 2016;136(3):567-573. doi:10.1016/j.jid.2015.11.025
Li B, Huang L, Lv P, et al. The role of Th17 cells in psoriasis. Immunol Res. 2020;68(5):296-309. doi:10.1007/s12026-020-09149-1
Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17-26. doi:10.1038/jid.2012.194
Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677-687. doi:10.1038/jid.2010.340
Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428-2437. doi:10.1038/jid.2011.234
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241-254. doi:10.1016/j.immuni.2004.07.007
Witte E, Kokolakis G, Witte K, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol. 2014;134(11):2757-2767. doi:10.1038/jid.2014.308
Brembilla NC, Stalder R, Senra L, Boehncke WH. IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin. Br J Dermatol. 2017;177(5):1458-1460. doi:10.1111/bjd.15358
Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23(5):613-619. doi:10.1016/j.coi.2011.07.006
Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600. doi:10.1038/nri3707
Keijsers RRMC, Hendriks AGM, van Erp PEJ, et al. In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17. J Invest Dermatol. 2014;134(5):1276-1284. doi:10.1038/jid.2013.526
Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018;9:1682. Published 2018 Aug 2. doi:10.3389/fimmu.2018.01682
Senra L, Mylonas A, Kavanagh RD, et al. IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. J Invest Dermatol. 2019;139(8):1732-1742.e17. doi:10.1016/j.jid.2019.01.021
Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252-2262. doi:10.4049/jimmunol.1201505
Montero-Vilchez T, Segura-Fernández-Nogueras MV, Pérez-Rodríguez I, et al. Skin Barrier Function in Psoriasis and Atopic Dermatitis: Transepidermal Water Loss and Temperature as Useful Tools to Assess Disease Severity. J Clin Med. 2021;10(2):359. Published 2021 Jan 19. doi:10.3390/jcm10020359
Stawczyk-Macieja M, Szczerkowska-Dobosz A, Rębała K, Purzycka-Bohdan D. Genetic background of skin barrier dysfunction in the pathogenesis of psoriasis vulgaris. Postepy Dermatol Alergol. 2015;32(2):123-126. doi:10.5114/pdia.2014.44003
Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-986. doi:10.1016/0190-9622(95)91336-x
Christophers E, Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res. 1987;279 Suppl:S48-S51. doi:10.1007/BF00585919
Schröder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol. 1999;31(6):645-651. doi:10.1016/s1357-2725(99)00013-8
Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151-1160. doi:10.1056/NEJMoa021481
Wolk K, Witte K, Witte E, et al. IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med. 2013;5(204):204ra129. doi:10.1126/scitranslmed.3006245
Gläser R, Harder J, Lange H, Bartels J, Christophers E, Schröder JM. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol. 2005;6(1):57-64. doi:10.1038/ni1142
Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309-1323. doi:10.1002/eji.200535503
Mallbris L, O'Brien KP, Hulthén A, et al. Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin. Exp Dermatol. 2002;11(6):584-591. doi:10.1034/j.1600-0625.2002.110611.x
Schröder JM. Antimicrobial peptides in healthy skin and atopic dermatitis. Allergol Int. 2011;60(1):17-24. doi:10.2332/allergolint.10-RAI-0292
Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel). 2014;7(5):545-594. Published 2014 May 13. doi:10.3390/ph7050545
Kao CY, Chen Y, Thai P, et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol. 2004;173(5):3482-3491. doi:10.4049/jimmunol.173.5.3482
Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271-2279. doi:10.1084/jem.20061308
Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186(2):1228-1239. doi:10.4049/jimmunol.0903907
Eyerich S, Wagener J, Wenzel V, et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol. 2011;41(7):1894-1901. doi:10.1002/eji.201041197
Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186(4):2613-2622. doi:10.4049/jimmunol.1003162
Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010;21(4):237-251. doi:10.1016/j.cytogfr.2010.04.002
Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13(1):21-38. doi:10.1038/nrd4176
Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961-969. doi:10.1001/jamadermatol.2015.0718
Yiu ZZN, Sorbe C, Lunt M, et al. Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. Br J Dermatol. 2019;180(4):894-901. doi:10.1111/bjd.17421
Kao LT, Lee CZ, Liu SP, Tsai MC, Lin HC. Psoriasis and the risk of pneumonia: a population-based study. PLoS One. 2014;9(12):e116077. Published 2014 Dec 26. doi:10.1371/journal.pone.0116077
Svedbom A, Mallbris L, Ståhle M. Risk of respiratory infection in patients with plaque psoriasis. J Am Acad Dermatol. 2021;85(4):1013-1015. doi:10.1016/j.jaad.2020.12.083
Kojanova M, Fialova J, Cetkovska P, et al. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428-434. doi:10.1111/ijd.13543
Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277-2294. doi:10.1111/jdv.13354
Balak DMW, Gerdes S, Parodi A, Salgado-Boquete L. Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. Dermatol Ther (Heidelb). 2020;10(4):589-613. doi:10.1007/s13555-020-00409-4
Mrowietz U, Sorbe C, Reich K, et al. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care. Eur J Dermatol. 2020;30(1):41-48. doi:10.1684/ejd.2020.3709
Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017;17(11):1363-1374. doi:10.1080/14712598.2017.1363884
Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726-1735. doi:10.1016/j.jid.2018.01.039
Dobry AS, Quesenberry CP, Ray GT, Geier JL, Asgari MM. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017;77(5):838-844. doi:10.1016/j.jaad.2017.07.047
Lee MP, Wu KK, Lee EB, Wu JJ. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. Cutis. 2020;106(4):199-205. doi:10.12788/cutis.0088
Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003;167(9):1279-1282. doi:10.1164/rccm.200206-563OC
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM. The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(5):1523-1526. doi:10.1016/j.jaad.2020.06.1014
Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292-294. doi:10.1016/j.jaad.2020.04.165
Witte-Händel E, Wolk K, Tsaousi A, et al. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. J Invest Dermatol. 2019;139(6):1294-1305. doi:10.1016/j.jid.2018.11.018
Sabat R, Wolk K, Loyal L, Döcke WD, Ghoreschi K. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359-377. doi:10.1007/s00281-019-00742-7
Solimani F, Meier K, Ghoreschi K. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. Eur J Immunol. 2021;51(5):1071-1075. doi:10.1002/eji.202149173
Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatol Ther (Heidelb). 2021;11(1):235-252. doi:10.1007/s13555-020-00475-8
Piaserico S, Gisondi P, Cazzaniga S, Naldi L. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020;21(5):749-751. doi:10.1007/s40257-020-00552-w
Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21(2):271-277. doi:10.1080/14712598.2021.1853698
Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628-637. doi:10.1111/bjd.19039
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11. Published 2020 Feb 14. doi:10.15585/mmwr.rr6901a1
Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824-834. doi:10.1111/jdv.16866
Papp KA, Haraoui B, Kumar D, et al. Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. J Cutan Med Surg. 2019;23(1):50-74. doi:10.1177/1203475418811335
Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003-1013. doi:10.1016/j.jaad.2013.06.046
Balagon MV, Walsh DS, Tan PL, et al. Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae. Int J Dermatol. 2000;39(1):51-58. doi:10.1046/j.1365-4362.2000.00862.x
O'Daly JA, Gleason J, Lezama R, Rodriguez PJ, Silva E, Indriago NR. Antigens from Leishmania amastigotes inducing clinical remission of psoriatic arthritis. Arch Dermatol Res. 2011;303(6):399 PubMed -415. doi: 10.1007/s00403-011-1133-0.
El-Darouti MA, Hegazy RA, Abdel Hay RM, Rashed LA. Study of T helper (17) and T regulatory cells in psoriatic patients receiving live attenuated varicella vaccine therapy in a randomized controlled trial. Eur J Dermatol. 2014;24(4):464-469. doi:10.1684/ejd.2014.2377
Diotallevi F, Campanati A, Radi G, et al. Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know. J Eur Acad Dermatol Venereol. 2021;35(7):e428-e430. doi:10.1111/jdv.17256
Dávila-Seijo P, Dauden E, Descalzo MA, et al. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. J Invest Dermatol. 2017;137(2):313-321. doi:10.1016/j.jid.2016.08.034
Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative. Australas J Dermatol. 2019;60(2):91-98. doi:10.1111/ajd.12895
Talamonti M, Galluzzo M, Chiricozzi A, et al. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. J Eur Acad Dermatol Venereol. 2020;34(12):e770-e772. doi:10.1111/jdv.16841
Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021;84(5):1254-1268. doi:10.1016/j.jaad.2020.12.058
Gisondi P, PIaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020;34(11):2499-2504. doi:10.1111/jdv.16774
Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR. Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries [published online ahead of print, 2020 Oct 30]. J Dermatolog Treat. 2020;1-5. doi:10.1080/09546634.2020.1808154
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461-2498. doi:10.1111/jdv.16915
den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689-695.
Pappas DA, Giles JT. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections?. Curr Opin Rheumatol. 2008;20(4):450-456. doi:10.1097/BOR.0b013e3282fcc345
Aragane Y, Riemann H, Bhardwaj RS, et al. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol. 1994;153(12):5366-5372.
Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010;11(3):789-806. Published 2010 Feb 26. doi:10.3390/ijms11030789
Kanda N, Watanabe S. IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in human keratinocytes. Eur J Immunol. 2008;38(5):1287-1296. doi:10.1002/eji.200738051
Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and Keratinocytes in Psoriasis. Int J Mol Sci. 2020;21(4):1275. Published 2020 Feb 13. doi:10.3390/ijms21041275
Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011;134(1):8-16. doi:10.1111/j.1365-2567.2011.03465.x
Kusagaya H, Fujisawa T, Yamanaka K, et al. Toll-like receptor-mediated airway IL-17C enhances epithelial host defense in an autocrine/paracrine manner. Am J Respir Cell Mol Biol. 2014;50(1):30-39. doi:10.1165/rcmb.2013-0130OC
Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12(12):1159-1166. Published 2011 Oct 12. doi:10.1038/ni.2156
Xu M, Lu H, Lee YH, et al. An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation. Immunity. 2018;48(4):787-798.e4. doi:10.1016/j.immuni.2018.03.019
Ha HL, Wang H, Claudio E, Tang W, Siebenlist U. IL-20-Receptor Signaling Delimits IL-17 Production in Psoriatic Inflammation. J Invest Dermatol. 2020;140(1):143-151.e3. doi:10.1016/j.jid.2019.06.127
Brandt K, Singh PB, Bulfone-Paus S, Rückert R. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 2007;18(3-4):223-232. doi:10.1016/j.cytogfr.2007.04.003
Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection [published correction appears in Science. 2009 Aug 21;325(5943):946]. Science. 2009;324(5934):1569-1572. doi:10.1126/science.1174182
Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111-119. doi:10.1177/2040622318759282
Sun R, Abraham C. IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant. Cell Mol Gastroenterol Hepatol. 2020;10(4):673-697. doi:10.1016/j.jcmgh.2020.05.007
Stephen-Victor E, Fickenscher H, Bayry J. IL-26: An Emerging Proinflammatory Member of the IL-10 Cytokine Family with Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses. PLoS Pathog. 2016;12(6):e1005624. Published 2016 Jun 23. doi:10.1371/journal.ppat.1005624
Scala E, Di Caprio R, Cacciapuoti S, et al. A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26. Br J Dermatol. 2019;181(5):1038-1045. doi:10.1111/bjd.17854
Murrieta-Coxca JM, Rodríguez-Martínez S, Cancino-Diaz ME, Markert UR, Favaro RR, Morales-Prieto DM. IL-36 Cytokines: Regulators of Inflammatory Responses and Their Emerging Role in Immunology of Reproduction. Int J Mol Sci. 2019;20(7):1649. Published 2019 Apr 3. doi:10.3390/ijms20071649
Wang P, Gamero AM, Jensen LE. IL-36 promotes anti-viral immunity by boosting sensitivity to IFN-α/β in IRF1 dependent and independent manners. Nat Commun. 2019;10(1):4700. Published 2019 Oct 16. doi:10.1038/s41467-019-12318-y
Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264-272. doi:10.1111/1346-8138.14139
Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020;34(9):1914-1923. doi:10.1111/jdv.16683
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40. doi:10.1016/j.jaad.2018.06.057
Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies. J Invest Dermatol. 2015;135(8):1946-1953. doi:10.1038/jid.2015.144
Published
Issue
Section
License
Copyright (c) 2022 Anna Balato, Emanuele Scala, Kilian Eyerich, Nicolo Costantino Brembilla, Andrea Chiricozzi, Robert Sabat, Kamran Ghoreschi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
